Nemaura Medical Inc. Announces Uplist to OTCQB

LOUGHBOROUGH, England--()--Nemaura Medical Inc. (OTC: NMRD), a medical technology company focused on the development and commercialization of sugarBEAT®, a wireless disposable adhesive skin-patch for adjunctive use by diabetics as a non-invasive and needle-free continuous glucose monitoring (CGM) system announced it has recently uplisted to the OTCQB Venture Market trading platform.

“We are pleased to announce our uplist to the OTC Quote Board, which we expect will enhance our visibility in the marketplace, broaden and diversify our investor base, and increase the liquidity of our common stock.”

Dr Faz Chowdhury, CEO of Nemaura Medical commented "We are pleased to announce our uplist to the OTC Quote Board, which we expect will enhance our visibility in the marketplace, broaden and diversify our investor base, and increase the liquidity of our common stock."

About Nemaura Medical, Inc.

Nemaura Medical is a medical technology company developing the wireless sugarBEAT® disposable adhesive skin-patch as a non-invasive, needle-free, pain-free and affordable continuous glucose monitoring (CGM) system for adjunctive use by diabetics. For more information, please visit www.nemauramedical.com.

Cautionary Statement Regarding Forward Looking Statements

The statements in this press release that are not historical facts, and may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to regulatory approvals and the success of Nemaura Medical’s ongoing studies, including the safety and efficacy of Nemaura Medical’s sugarBEAT® CGM system, the failure of future development and preliminary marketing efforts, Nemaura Medical’s ability to secure additional commercial partnering arrangements, risks and uncertainties relating to Nemaura Medical and its partners’ ability to develop, market and sell sugarBEAT®, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to sugarBEAT®. These and other risks and uncertainties are identified and described in more detail in Nemaura Medical’s filings with the Securities and Exchange Commission, including, without limitation, its Annual Report on Form 10-K for the current year, its Quarterly Reports on Form 10-Q, and its Current Reports on Form 8-K. Nemaura Medical undertakes no obligation to publicly update or revise any forward-looking statements.

Contacts

Nemaura Medical
Investors / Media contact:
Bashir Timol
Director of Strategy & Corporate Development
bashir.timol@nemauramedical.com

Recent Stories

RSS feed for Nemaura Medical Inc.

Release Summary

Nemaura Medical Inc. announces uplist to OTCQB

Nemaura Medical Inc.